Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

Subjects

Subjects :

Adenocarcinoma of Lung
Afatinib
Female
Humans
Male
Adenocarcinoma drug therapy
Antineoplastic Combined Chemotherapy Protocols therapeutic use
ErbB Receptors genetics
Lung Neoplasms drug therapy
Quinazolines therapeutic use

Details

Language :

English

ISSN :

1527-7755

Volume :

32

Issue :

8

Database :

MEDLINE

Journal :

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication Type :

Editorial & Opinion

Accession number :

24493720

Full Text :

https://doi.org/10.1200/JCO.2013.52.8794